The present invention provides an application of CST1 in prevention and/or treatment of liver immune dysregulation diseases. Specifically, the present invention provides an application of a CST1 gene, or a protein thereof, or a promoter thereof for preparing a composition or a preparation. The composition or the preparation is used for prevention and/or treatment of liver immune dysregulation diseases.

The present invention provides an application of CST1 in prevention and/or treatment of liver immune dysregulation diseases. Specifically, the present invention provides an application of a CST1 gene, or a protein thereof, or a promoter thereof for preparing a composition or a preparation. The composition or the preparation is used for prevention and/or treatment of liver immune dysregulation diseases.

Methods for treating and/or alleviating acute respiratory distress syndrome in a patient diagnosed with or at risk of developing acute respiratory distress syndrome are disclosed. The methods comprise administering a therapeutically effective amount of an aerosolized collagenase to the patient, wherein the collagenase breaks down scar tissue in the lung, thereby treating the ARDS, or delaying or preventing onset of ARDS.

Methods for treating and/or alleviating acute respiratory distress syndrome in a patient diagnosed with or at risk of developing acute respiratory distress syndrome are disclosed. The methods comprise administering a therapeutically effective amount of an aerosolized collagenase to the patient, wherein the collagenase breaks down scar tissue in the lung, thereby treating the ARDS, or delaying or preventing onset of ARDS.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.

Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.

Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.

Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.